Remarkably, the p38α inhibitor ARRY-371797 improved left ventricular dilation and fractional shortening in mutant Lmna (H222P/H222P) mice,31 and this compound is currently under assessment in Phase 2 and 3 clinical trials in patients with LMNA-related dilated cardiomyopathy (ClinicalTrials.gov Identifiers: NCT02351856, NCT03439514). Here, LMNA is linked to Ventriculomegaly.